MeiraGTx   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03001310
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

MeiraGTx, LLC | MeiraGTx UK II Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

aav5-rpgr (2 trials)

Drugs in Phase 2 Trials (4)

aav2haqp1 (2 trials)

aav-gad (2 trials)

aav-rpgr (1 trial)

raav.hcnga3 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Color Vision Defects (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Xerostomia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 5